← Back to Clinical Trials
Recruiting Phase 2 NCT06194851

NCT06194851 Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06194851
Status Recruiting
Phase Phase 2
Sponsor VA Office of Research and Development
Condition Post-Traumatic Stress Disorder (PTSD)
Study Type INTERVENTIONAL
Enrollment 240 participants
Start Date 2024-10-28
Primary Completion 2028-09-30

Trial Parameters

Condition Post-Traumatic Stress Disorder (PTSD)
Sponsor VA Office of Research and Development
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 240
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-28
Completion 2028-09-30
Interventions
Oxytocin nasal spraySaline nasal sprayBrief Cognitive-Behavioral Conjoint Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Leveraging veterans' intimate relationships during treatment for posttraumatic stress disorder (PTSD) has the potential to concurrently improve PTSD symptoms and relationship quality. Brief Cognitive-Behavioral Conjoint Therapy (bCBCT) is a manualized treatment designed to simultaneously improve PTSD and relationship functioning for couples in which one partner has PTSD. Although efficacious in improving PTSD, the effects of CBCT on relationship satisfaction are small, especially among Veterans. Pharmacological augmentation of bCBCT with intranasal oxytocin, a neurohormone that influences mechanisms of trauma recovery and social behavior, may help improve the efficacy of bCBCT. The purpose of this randomized placebo-controlled trial is to compare the clinical and functional outcomes of bCBCT augmented with intranasal oxytocin (bCBCT + OT) versus bCBCT plus placebo (bCBCT + PL). The investigators will also explore potential mechanisms of action: communication, empathy, and trust.

Eligibility Criteria

Inclusion Criteria: Inclusion criteria for Veteran: 1. Be a Veteran (age 18 or older) with a current DSM-5 diagnosis of PTSD (as assessed by the CAPS-5 with a minimum severity score of 25) no less than 3 months after the index trauma occurred (to allow for potential natural recovery) 2. Be on a stable psychoactive medication regimen for at least 4 weeks (if applicable) 3. Be enrolled and eligible to receive care at the VASDHS Inclusion criteria for Partner: 4. Be an intimate partner (age 18 or older) who is willing to participate in the intervention (partners can also be Veterans but cannot meet criteria for possible PTSD per the PCL-5) Inclusion criteria for Veteran and Partner: 5. Be married, or cohabitating for at least 6 months 6. Willing to be randomized into either treatment condition (bCBCT + OT or bCBCT + PL) 7. Agree to have assessment and treatment sessions audio/video recorded 8. Agree not to receive other individual trauma-focused psychotherapy for PTSD or any form of conjo

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology